Fortress Biotech Pref A
FBIOP
Fortress Biotech Pref A (FBIOP) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.08
- EPS estimate
- −$0.20
- EPS surprise
- +60.00%
- Revenue surprise
- +2.28%
- Revenue
- $18.7M
- Revenue estimate
- $18.3M
- Reported
- Aug 13, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | −$0.20 | −$0.08 | +60.00% | $18.7M | SEC |
| Q1 2026 | May 14, 2026 | −$0.22 | $2.82 | +1381.82% | $16.0M | SEC |
| Q4 2025 | Mar 31, 2026 | $0.11 | −$0.15 | −236.36% | $16.1M | SEC |
| Q3 2025 | Nov 14, 2025 | −$0.42 | $0.11 | +126.19% | $17.6M | SEC |
| Q2 2025 | Aug 14, 2025 | −$0.36 | $0.45 | +225.00% | $16.4M | SEC |
| Q1 2025 | May 15, 2025 | −$0.50 | −$0.48 | +3.03% | $13.1M | SEC |
| Q4 2024 | Mar 31, 2025 | −$0.75 | −$0.17 | +77.43% | $15.1M | SEC |
| Q3 2024 | Nov 14, 2024 | −$0.60 | −$0.76 | −27.73% | $14.6M | SEC |
| Q2 2024 | Aug 13, 2024 | −$1.22 | −$0.73 | +40.33% | $14.9M | SEC |
| Q1 2024 | May 15, 2024 | −$1.73 | −$1.03 | +40.46% | $13.0M | SEC |
| Q4 2023 | Mar 28, 2024 | −$1.65 | −$0.78 | +52.58% | $19.9M | SEC |
| Q3 2023 | Nov 14, 2023 | −$3.21 | −$0.94 | +70.68% | $34.8M | SEC |
| Q2 2023 | Aug 14, 2023 | −$3.41 | −$3.60 | −5.49% | $17.4M | SEC |
| Q1 2023 | May 15, 2023 | −$3.00 | −$3.15 | −5.00% | $12.4M | SEC |
| Q4 2022 | Mar 30, 2023 | −$3.33 | −$4.50 | −35.14% | $16.4M | SEC |
| Q3 2022 | Nov 14, 2022 | −$4.05 | −$3.75 | +7.41% | $16.5M | SEC |
| Q2 2022 | Aug 11, 2022 | −$2.81 | −$3.60 | −28.25% | $18.9M | SEC |
| Q1 2022 | May 12, 2022 | −$2.97 | −$2.70 | +9.09% | $23.9M | SEC |
| Q4 2021 | Mar 28, 2022 | $1.25 | −$5.70 | −556.00% | $18.3M | — |
| Q3 2021 | Nov 15, 2021 | −$1.23 | −$3.90 | −218.37% | $21.1M | — |
Quarterly revenue
Frequently asked questions
When did Fortress Biotech Pref A (FBIOP) last report earnings?
Fortress Biotech Pref A last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did FBIOP beat earnings estimates?
Yes. Fortress Biotech Pref A reported EPS of −$0.08 for Q2 2026 against a −$0.20 estimate — a 60.00% beat.
How much revenue did FBIOP report last quarter?
Fortress Biotech Pref A reported $18.7M in revenue for Q2 2026, against a consensus estimate of $18.3M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.